Foghorn and Lilly will end further collaboration activities after FHD-909 failed to demonstrate sufficient efficacy, while Foghorn cuts its workforce by approximately 40% and extends its cash runway into the second half of 2029.
Key Investor Takeaways
- Foghorn Therapeutics (NASDAQ:FHTX) and Lilly decided not to advance FHD-909 into clinical expansion following a review of Phase 1 dose-escalation data.
- Management said FHD-909 achieved selective SMARCA2 targeting and a favourable safety profile, but efficacy was insufficient to justify further development.
- The companies will also discontinue their Selective SMARCA2 degrader programme and do not anticipate additional collaboration activities.
- Foghorn is reducing its workforce by approximately 40% and restructuring operations to concentrate spending on its proprietary pipeline.
- The cost reductions are expected to provide cash to fund priority programmes into the second half of 2029.
Why FHTX Stock Is in Focus
Foghorn Therapeutics is ending development of FHD-909 with Lilly after Phase 1 clinical results failed to provide the efficacy needed to move the programme into its expansion stage.
FHD-909, also known as LY4050784, was designed as an orally available small molecule selectively targeting SMARCA2 over the closely related SMARCA4 protein.
According to Foghorn, the candidate demonstrated a favourable safety profile and achieved exposures exceeding the company’s preclinical targets. However, CEO Adrian Gottschalk said the underlying SMARCA2/4 synthetic lethality biology did not translate into the level of clinical efficacy required for continued development.
The decision also extends to the Selective SMARCA2 degrader programme. Foghorn and Lilly do not expect to conduct further activities under their collaboration.
Why This Matters for Investors
The FHD-909 discontinuation removes a clinical-stage programme from Foghorn’s development pipeline and effectively brings its collaboration activities with Lilly to an end.
For investors, the key shift is therefore toward Foghorn’s wholly owned pipeline. The company is redirecting financial and development resources toward programmes it identifies as having greater potential, including its EP300 degrader, a novel oral immunology and inflammation programme, its CBP degrader and its induced proximity platform.
That transition comes with a substantial reduction in operating infrastructure. Foghorn plans to cut approximately 40% of its workforce and further align its operating structure.
While the restructuring reflects the loss of FHD-909 as a development opportunity, it may give Foghorn considerably more time to advance its remaining assets. Management said the changes should provide sufficient cash to fund its priority programmes into the second half of 2029.
The investment narrative consequently shifts from the clinical prospects of the Lilly-partnered SMARCA2 programme toward whether Foghorn can translate its drug-design capabilities into progress across its proprietary portfolio.
What to Watch Next
Attention will now move to development milestones for Foghorn’s EP300 and CBP degrader programmes, its oral immunology and inflammation programme and the induced proximity platform.
Investors can also watch the implementation of the approximately 40% workforce reduction, the company’s spending following the restructuring and whether its stated cash runway into the second half of 2029 remains sufficient as priority programmes approach clinical development.